photo of Gilmore O'Neill

Gilmore O'Neill, MB, MMSC

Executive Vice President, R&D and Chief Medical Officer

“I met the parents of a young boy with Duchenne muscular dystrophy. They said, ‘We’re so grateful you’re developing this gene therapy, but we’re really worried because our son is deteriorating fast.’ Well, we have a sort of sacred responsibility to help him and all the other boys he represents. We cannot stumble. We cannot slow down. We all feel that urgency here.”

Dr. Gilmore O’Neill joined Sarepta in June 2018. He leads our research, clinical development, medical affairs, pharmacovigilance, and regulatory affairs functions.

Like many, Gilmore was drawn to Sarepta’s focus—intense, even by the standards of the biotech community—on patients with devastating rare diseases. Unlike many, he came with direct patient experience from years as a practicing neurologist.

“I met the parents of a young boy with Duchenne muscular dystrophy. They said, ‘We’re so grateful you’re developing this gene therapy, but we’re really worried because our son is deteriorating fast.’ Well, we have a sort of sacred responsibility to help him and all the other boys he represents. We cannot stumble. We cannot slow down. We all feel that urgency here.”

Gilmore joined Sarepta after spending 15 years at Biogen, holding leadership roles in development programs for Alzheimer’s disease, movement disorders, neurology, multiple sclerosis, pain, neuromuscular disease, gene and cell therapy, and rare diseases. Gilmore’s responsibilities included global marketing approvals for Tecfidera, Zinbryta, Plegridy, and Spinraza. While at Biogen, he served as a clinical instructor in neurology at Harvard Medical School.

Gilmore, a board-certified neurologist, received a Bachelor of Medicine degree at University College Dublin and a Master of Medical Sciences degree from Harvard University. He completed his residency training in neurology at Massachusetts General Hospital, where he also served as Chief Resident. He serves on the board of the Massachusetts Biotechnology Council. He is the recipient of numerous awards in science and medicine, has authored many publications on multiple sclerosis, and lectures in the United States and globally on advances in neurology and neurological research.